Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (14,8 Mio. €): CardioReGenix: Entwicklung von Gentherapien der nächsten Generation für Herz-Kreislauf-Erkrankungen Hor01.01.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
CardioReGenix: Entwicklung von Gentherapien der nächsten Generation für Herz-Kreislauf-Erkrankungen
WHO estimates 17.7 million people die each year from cardiovascular disease (CVD), an estimated 31% of all deaths worldwide. While progress with conventional treatments is making incremental gains, there remains a need to develop innovative therapeutic approaches. Gene therapy has gained significant momentum, mainly for treatment of rare monogenetic diseases. Marketing authorization for gene therapy products has not impacted diseases such as CVD. Recent, deeper understanding of the molecular/cellular mechanisms of CVD and technology associated with more efficient and safer gene therapy vectors has allowed new opportunities for development of next-generation ATMPs for CVD. CardioReGenix focuses on technological innovations for the treatment of CVD, in particular heart failure and myocardial ischemia. We aim to overcome bottlenecks in gene therapy for CVD by (i) maximizing cardiac-specific gene expression; (ii) maximizing cardiac-specific gene delivery; (iii) reducing adverse immune responses; (iv) optimizing manufacturing for research and clinical-grade ATMPs ; (v) validate new promising targets using in vitro and preclinical models; (vi) undertaking first-in-man studies; (vii) developing and implementing an exploitation and valorization strategy with strong EU SME involvement. CardioReGenix is a high risk/high gain project supported by robust preliminary data and multi-disciplinary consortium harnessing know-how in vector development, GMP manufacturing, preclinical and clinical cardiology, regulation of ATMP and liaising with EMA, business development and clinical translation. CardioReGenix will (i) strengthen Europe's competitive position in gene therapy development for CVD; (ii) improve the prospect of successfully treating patients suffering from CVD by gene therapy and (iii) develop and refine the latest gene therapy platforms that go significantly beyond the state of the art.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| A2F Associates Ltd. | 718.295 € |
| Asphalion SL | 310.035 € |
| Batavia Biosciences B.V. | 955.908 € |
| CARDIOR PHARMACEUTICALS GmbH | 908.250 € |
| CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL | 1.411.526 € |
| FINVECTOR Oy | 239.708 € |
| ITA-SUOMEN YLIOPISTO | 2.566.115 € |
| King's College London | 1.013.675 € |
| MEDIZINISCHE HOCHSCHULE HANNOVER | 1.193.623 € |
| 677.750 € | |
| Stichting Amsterdam UMC | 1.106.751 € |
| The University of Edinburgh | 1.424.114 € |
| Vrije Universiteit Brussel | 2.314.025 € |
Quelle: https://cordis.europa.eu/project/id/825670
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "A2F Associates Ltd. - EU-Förderung (14,8 Mio. €): CardioReGenix: Entwicklung von Gentherapien der nächsten Generation für Herz-Kreislauf-Erkrankungen"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
